Modakafusp alfa

• Description :

  Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice[1][2][3][4].

• Product Name Alternative :

  TAK-573

• UNSPSC :

  12352203

• Target :

  CD38

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/modakafusp-alfa.html

• Purity :

  96.22

• Solubility :

  10 mM in DMSO

• Smiles :

  [Modakafuspalfa]

• Molecular Weight :

  (183.48 kDa)

• References & Citations :

  [1]Dan T. Vogl MD, et al. TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma.Blood. 2020, 136 (1), 37-38. |[2]Fatholahi M, et al. TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFNα) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo[J]. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19 (10) : e116.|[3]Hara T, et al. A murine reactive version of TAK-573 (anti-CD38 attenuated IFNα fusion protein) shows immunomodulatory and antitumor activity, alone and in combination with standard-of-care agents, in IFNa-insensitive, immunocompetent murine multiple myeloma tumor models[J]. Cancer Research, 2020, 80 (16_Supplement) : 5546-5546.|[4]Bruins W S C, et al. Modakafusp alfa (TAK-573), a novel CD38-targeting attenuated interferon-alpha immunocytokine, kills MM cells via NK cell activation[J]. Blood, 2022, 140 (Supplement 1) : 4236-4237.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2

• CAS Number :

  [2254522-19-3]